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Summary Background This phase I study evaluated the safe-
ty and tolerability, pharmacokinetics and pharmacodynamics,
immunogenicity, and antitumor activity of pembrolizumab in
Japanese patients with advanced solid tumors. Methods
Following an initial dose and a 28-day rest (cycle 1),
pembrolizumab was administered as an intravenous infusion
at escalating doses (2 or 10mg/kg) every 2 weeks (Q2W) until
disease progression or unacceptable toxicity. Adverse events
(AEs) were assessed using CTCAE v4.0, and tumor response
was assessed using both RECIST v1.1 and immune-related
response criteria (irRC). Full pharmacokinetic sampling was
performed during cycle 1. Results Three patients received
pembrolizumab at 2.0 mg/kg and seven at 10 mg/kg. No
dose-limiting toxicities were observed during cycle 1. Eighty
percent of patients experienced drug-related AEs (mostly
grade 1 or 2); the most common drug-related AEs were nau-
sea, malaise, pyrexia, and aspartate aminotransferase/alanine
transaminase (AST/ALT) elevations (n=2 each). No drug-
related grade 4 or 5 AEs occurred. Immune-related AEs com-
prised grade 3 ALT elevation (n=1), grade 3 AST elevation
(n=1), grade 1 pneumonitis (n= 1), and grade 1 thyroid-
stimulating hormone elevation (n = 1). The safety and
pharmacokinetic profiles of Japanese patients were similar to
those previously reported for Caucasian patients. A partial
tumor response was observed in one patient with non-small-
cell lung cancer (NSCLC) and in one patient with melanoma.
Conclusions Pembrolizumab at both 2 and 10 mg/kg Q2W
was well tolerated in Japanese patients with advanced solid
tumors and showed encouraging anti-tumor activity against
melanoma and NSCLC.
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Introduction
The PD-1 pathway represents a major immune control switch
that may be engaged by tumor cells to overcome active T-cell
immune surveillance [1]. The ligands for PD-1 (PD-L1 and
PD-L2) are constitutively expressed or can be induced in var-
ious tumors, including melanoma [2–5]. The high expression
of PD-L1 (and to a lesser extent, PD-L2) on tumor cells is
correlated with poor prognosis and poor survival in various
cancer types, including renal cell carcinoma, pancreatic carci-
noma, hepatocellular carcinoma, ovarian carcinoma, and non-
small-cell lung cancer (NSCLC) [6–10]. Furthermore, it has
been suggested that PD-1 regulates tumor-specific T-cell ex-
pansion in patients with melanoma [11]. Preclinical in vitro
and in vivo experiments have shown that PD-1 and/or PD-L1
blockade using monoclonal antibodies enhances tumor cell-
specific T-cell activation, cytokine production, anti-tumor ef-
fector mechanisms, and the clearance of tumor cells by the
immune system [12–16]. PD-1 and PD-L1 inhibitors have
validated PD-1 as an attractive target for clinical therapeutic
intervention. PD-1 inhibition was tested in a clinical study of
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patients with a range of solid tumor types, and promising
clinical activity was noted in multiple tumor types, including
melanoma and NSCLC [17].
Pembrolizumab (formerly known as MK-3475) is a potent,
highly selective, IgG4-k humanized monoclonal antibody that
prevents PD-1 from binding with PD-L1 and PD-L2. This
agent was generated by grafting the variable region sequences
of a mouse antihuman PD-1 antibody onto a human IgG4-k
isotype framework containing a stabilizing S228P mutation of
the Fc region. Pembrolizumab exhibited high affinity for the
PD-1 receptor, strong inhibition of PD-L1 and PD-L2, and
robust activity in a functional ex vivo T-cell modulation assay
using human donor blood cells (data on file; Merck & Co.,
Inc.).
A first-in-human phase 1 study was conducted to evaluate
the safety, pharmacokinetics, and pharmacodynamics of
pembrolizumab in non-Japanese patients with advanced solid
tumors. No dose-limiting toxicities (DLTs) were observed,
and the maximum administered dose (MAD) was 10 mg/kg
every 2 weeks (Q2W). Pharmacokinetic and pharmacody-
namic analyses showed that the lowest dose with the full po-
tential for antitumor activity was 2 mg/kg every 3 weeks
(Q3W) [18].
In the present study, the safety and tolerability, pharmaco-
kinetics (PK), and immunogenicity of pembrolizumab were
investigated in Japanese patients with advanced solid tumors.




This study was conducted based on the Declaration of
Helsinki and the Guidelines for the Clinical Evaluation
Methods of Anti-Cancer Drugs in Japan (Japanese Ministry
of Health, Labour, and Welfare notification, November 1,
2005). The study was approved by the institutional review
board of each study site.
The main eligibility criteria were as follows: a histological-
ly or cytologically confirmed diagnosis of locally advanced or
metastatic solid tumors in a patient who had experienced dis-
ease progression while on standard therapy or in a patient
intolerant of, or not eligible for standard therapy; a patient
age of 20 years or older; an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1; and adequate
hematologic, hepatic, and renal functions. The exclusion
criteria included the administration of chemotherapy, radio-
therapy, or biological therapy in the 4 weeks (2 weeks for
palliative radiotherapy and kinase inhibitors) prior to enroll-
ment; previous treatment with a PD-1, PD-L1, or cytotoxic T-
lymphocyte-associated protein 4 inhibitor; untreated and/or
unstable central nervous system metastasis; or the presence
of autoimmune disease.
All patients provided informed consent, and the study was
conducted in accordance with current Good Clinical Practice
standards. This study was registered at ClinicalTrials.gov as
NCT01840579.
Study design and evaluation
This study was an open-label, non-randomized, phase 1 study
of pembrolizumab in Japanese patients with advanced solid
tumors that was conducted at two sites in Japan. This study
was designed to investigate the safety and tolerability, PK,
immunogenicity, and anti-tumor activity of pembrolizumab
monotherapy. Pembrolizumab was administered as a 30-min
intravenous (i.v.) infusion at a dose of 2 or 10 mg/kg. Dose
escalation was conducted using the conventional B3+3 de-
sign,^ with cohorts of three patients sequentially enrolled at
pembrolizumab doses of 2 and 10 mg/kg administered on
days 1 and 28 and Q2W thereafter until disease progression
or intolerable toxicity occurred. The initial 28 days after the
first administration (cycle 1) were regarded as the DLT evalu-
ation period. Three or six patients were enrolled at each dose
based on the toxicity probability intervals [19]. In the DLT
assessments, if none of the three patients or none/one of the
six patients had a DLT at a certain dose, that dose was consid-
ered to be tolerable.
Adverse events (AEs) were graded using the National
Cancer Institute Common Terminology Criteria for AEs, ver-
sion 4.0. A DLT was defined as any of the following events
occurring during cycle 1 (the initial 28 days): grade 4 neutro-
penia lasting for ≥7 days; grade 3 or 4 neutropenia with a fever
>38.5 °C and/or infection requiring antibiotic or anti-fungal
treatment; grade 4 thrombocytopenia; grade 4 non-
hematologic toxicity; or a grade 3 non-hematologic toxicity
(laboratory value) persisting for >1 week or requiring medical
intervention.
Anti-tumor activity was evaluated at baseline and every
6 weeks according to the Response Evaluation Criteria In
Solid Tumors, version 1.1 (RECIST v1.1) and the immune-
related response criteria (irRC) [20].
Pharmacokinetics and immunogenicity (presence
of anti-drug antibody)
Blood samples for the PK analyses were collected predose,
postdose (<30 min after infusion), and 6, 24, and 48 h after
the start of the first infusion; on days 8, 15, 22, and 29 of cycle
1; predose and postdose in cycle 2 and every other cycle there-
after for the first 12 months; and 30 days after the last
pembrolizumab dose. The pembrolizumab serum concentra-
tions were quantified using a validated electrochemiluminescent
assay (lower limit of quantification, 10 ng/mL). The PK data are
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described using a noncompartmental approach. Blood samples
for anti-drug antibody (ADA) analyses were collected predose
and 24 h after the start of the first infusion, predose in cycle 2
and every other cycle thereafter for the first 12 months, and
30 days after the last pembrolizumab dose.
The presence of ADA was determined using bridging
electrochemiluminescence and was evaluated using the stan-
dard three-step method consisting of a screening test, a con-
firmation test, and an antibody titer test. ADAwas determined
to be positive if the result for at least one predose or postdose
sample was positive on the confirmation test.
PD-L1 expression
PD-L1 expression was measured using immunohistochemis-
try performed on formalin-fixed, paraffin-embedded tissue
sections at QualTek Clinical Laboratories. PD-L1 positivity
was defined as staining in ≥1 % of the tumor cells (modified
proportion score) or stroma using immunohistochemistry with
the PD-L1 22C3 antibody.
Results
Patient characteristics
Ten Japanese patients with advanced solid tumors were en-
rolled and were evaluated in this study; three patients were
treated with 2 mg/kg Q2W and seven patients were treated
with 10 mg/kg Q2W. The baseline characteristics of the pa-
tients are summarized in Table 1. The age range was 52.0–
91.0 years (median: 62.0 years), and the most frequent solid
tumors were NSCLC (5/10, 50.0 %) and melanoma (3/10,
30.0 %). The median number of prior chemotherapy regimens
was 5 (range, 0–13). The median number of treatments was 4
(range, 1–18). At the time of data cutoff, nine of the ten pa-
tients had discontinued pembrolizumab treatment: one be-
cause of an adverse event (grade 4 cerebral infarction that
was considered by the investigator to be unrelated to
pembrolizumab treatment) and eight because of disease
progression.
Safety and tolerability
The DLTs occurring during cycle 1 were evaluated. One pa-
tient treated with pembrolizumab 10 mg/kg was excluded
from the DLT evaluation because the patient discontinued
the study because of disease progression during the DLTeval-
uation period. Therefore, that patient was replaced with a new
patient for the DLT evaluation. No DLTs were observed in the
three patients treated with 2 mg/kg or in the six patients treated
with 10 mg/kg. The drug-related AEs reported for all treat-
ment cycles at both dose levels are summarized in Table 2.
Eighty percent of patients experienced drug-related AEs
(mostly grade 1 or 2). The most common AEs related to
pembrolizumab treatment were nausea, malaise, pyrexia, ele-
vated alanine transaminase (ALT) levels, and elevated aspar-
tate aminotransferase (AST) levels (2/10 [20 %] for each AE).
No drug-related grade 4 or grade 5 AEs occurred in this study.
None of the patients discontinued pembrolizumab treatment
because of a drug-related AE. One patient (a 53-year-old man)
with advanced NSCLC developed grade 3 ALT elevation,
grade 3 AST elevation, and grade 1 pneumonitis (onset, day
42 for each); after the discontinuation of pembrolizumab treat-
ment, he developed grade 3 hyponatremia (onset, day 56). The
grade 3 ALT/AST elevations resolved after treatment with
glycyrrhetinic acid, and the grade 3 hyponatremia resolved
with sodium chloride supplement. Overall, one case each of
grade 3 ALT elevation, grade 3 AST elevation, grade 1 pneu-
monitis, and grade 1 thyroid-stimulating hormone (TSH) ele-
vation were reported as immune-related AEs by the
investigators.
Pharmacokinetic and immunogenicity evaluation
The mean serum concentration profiles for pembrolizumab
are shown in Fig. 1, and descriptive statistics for the PK pa-
rameters are given in Table 3 and Fig. 2. The serum concen-
tration of pembrolizumab following the first i.v. administration
Table 1 Baseline patient characteristics
Characteristic Value

















Extramammary Paget’s disease 1
Number of prior systemic therapies
Median 5
Range 0–13
ECOG Eastern Cooperative Oncology Group
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Table 2 All grades of adverse








All Grades Grade 3 All Grades Grade 3 All Grades Grade 3
Blood and lymphatic system disorders
Anemia 0 0 1 0 1 0
Neutropenia 0 0 1 0 1 0
Thrombocytopenia 0 0 1 0 1 0
Gastrointestinal disorders
Nausea 1 1 1 0 2 0
General disorders and administration site conditions
Malaise 1 0 1 0 2 0
Pyrexia 1 0 1 0 2 0
Fatigue 1 0 0 0 1 0
Infections and infestations
Infection 0 0 1 0 1 0
Investigations
ALT elevation 0 0 2 1 2 1
AST elevation 0 0 2 1 2 1
Blood cholesterol elevation 1 0 0 0 1 0
Blood TSH elevation 0 0 1 0 1 0
Weight reduction 0 0 1 0 1 0
Metabolism and nutrition disorders
Dehydration 0 0 1 0 1 0
Hyperglycemia 0 0 1 0 1 0
Hyperkalemia 0 0 1 0 1 0
Hypertriglyceridemia 1 0 0 0 1 0
Hypokalemia 0 0 1 0 1 0
Hyponatremia 0 0 1 1 1 1
Respiratory, thoracic, and mediastinal disorders
Exertional dyspnea 0 0 1 0 1 0
Pneumonitis 0 0 1 0 1 0
Skin and subcutaneous tissue disorders
Drug eruption 0 0 1 0 1 0
Rash 0 0 1 0 1 0
Urticaria 0 0 1 0 1 0
AEs related to pembrolizumab were grade 1, 2, or 3 in severity, with no grade 4 or 5 AEs reported
Fig. 1 Serum concentration–time
profiles of pembrolizumab
following the first administration.
Symbols and error bars indicate
the mean ± SD
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decreased slowly in Japanese patients with advanced solid tu-
mors. The geometric mean terminal half-lives (t1/2) for
pembrolizumab following the first i.v. administration were
18.4 and 18.1 days at doses of 2 and 10 mg/kg, respectively,
in Japanese patients. For doses of 2 and 10mg/kg, respectively,
the geometric mean (and coefficient of variation) values for the
clearance (CL) were 2.46 (45 %) and 2.93 (56 %) mL/day/kg
and for the terminal phase volume (Vz) were 65.3 (21 %) and
76.5 (34 %) mL/kg. The t1/2, CL, and Vz values were very
similar for doses of 2 and 10 mg/kg in Japanese patients with
advanced solid tumors. Exposure to pembrolizumab, as
reflected by the total area under the concentration–time curve
(AUC0-∞) and maximum concentration (Cmax), following the
first i.v. administration of pembrolizumab at doses of 2 and
10 mg/kg generally increased in a dose-proportional manner
in Japanese patients. The PK profiles of pembrolizumab,
which has a low clearance, a limited volume of distribution,
and a long t1/2, are typical of therapeutic antibodies. The trough
concentration increased during repeated dosing at 2 or 10 mg/
kg Q2W. Based on the t1/2 (18 days) and the dose interval
(2 weeks), approximately 3.5 months (cycle 8) were consid-
ered necessary to achieve a steady state. However, only two
patients treated with 2 mg/kg and one patient treated with
10 mg/kg were still receiving pembrolizumab at cycle 8.
Considering the limited PK data available for doses of 2 and
10mg/kg beyond cycle 8, the steady state trough concentration
could not be determined based on the observed PK data.
ADA was not detected at any time in screening assays
from predose through to cycle 18 (day 140), except in a
predose assay performed during cycle 1 in one patient;
















































Cmaxmaximum observed serum concentration, Tmax time of maximum observed serum concentration, AUC0–28 area under the concentration–time curve
from day 0 to day 28, AUC0–∞ area under the concentration–time curve from day 0 to infinity, t1/2 elimination half-life, Vz the terminal phase volume, CL
clearance, GM geometric mean, CV coefficient of variation
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Fig. 2 PK parameters versus dose following the first administration of
pembrolizumab in Japanese and non-Japanese patients with advanced
solid tumors. AUC0-∞ total area under the concentration–time curve,
Cmax maximum concentration, CL clearance, Vz the terminal phase
volume
however, the results of the confirmatory assay were neg-
ative for this patient.
Antitumor activity and PD-L1 expression
As an exploratory objective, the tumor response to
pembrolizumab was evaluated according to the RECIST
v1.1 and irRC criteria. One patient with extramammary
Paget’s disease was excluded from the tumor response assess-
ment because the patient did not have any measurable lesions
at the study baseline. Among the nine patients who were eval-
uated, partial responses (as determined by an investigator re-
view according to RECIST v1.1) were observed in two pa-
tients (22.2 %) treated with pembrolizumab 10 mg/kg Q2W;
one patient (a 91-year-old man) had metastatic melanoma
(time to response: 46 days), and the other (a 53-year-old
man) had NSCLC (time to response: 41 days). The two pa-
tients also had partial responses as determined by an investi-
gator review according to irRC. The patient with advanced
NSCLC developed immune-related AEs (grade 3 ALT/AST
elevations and grade 1 pneumonitis) at the same time as the
observation of the partial response. At the time of data cutoff,
the patient with advanced metastatic melanoma who had
achieved a partial response was continuing to receive
pembrolizumab treatment because, despite disease progres-
sion according to RECIST v1.1, disease progression was not
evident according to irRC (response duration: more than
225 days) (Fig. 3). Tumor tissue from five patients was avail-
able to undergo a PD-L1 expression immunohistochemistry
assay. PD-L1 expression was positive in tumor samples from
two patients and negative in tumor samples from three pa-
tients. No responses were observed in the two patients with
PD-L1-positive tumors by an investigator review whereas a
partial response was observed in one of the three patients with
PD-L1-negative tumors.
Discussion
The primary objective of the present study was to investigate
the safety and tolerability of single-agent pembrolizumab ad-
ministered in Japanese patients with advanced solid tumors.
The dosing schedules in the present study were selected based
on the results of a phase 1 study of pembrolizumab in non-
Japanese patients with advanced solid tumors. The previous
study showed that the MAD was 10 mg/kg Q2W, and the
lowest dose with the full potential for antitumor activity was
2 mg/kg Q3W [18]. No DLTs were observed at either dose in
the present study. The most common drug-related AEs were
nausea, malaise, pyrexia, and AST/ALT elevations (n= 2
each). One case each of grade 3 ALT elevation, grade 3 AST
elevation, grade 1 pneumonitis, and grade 1 TSH elevation
were reported as immune-related AEs. The AEs observed in
the present study have also been reported for clinical studies of
pembrolizumab in non-Japanese patients. Although the num-
ber of Japanese patients was limited, the safety profile of
pembrolizumab in Japanese patients with advanced solid tu-
mors in the present study was generally consistent with that
observed previously in non-Japanese patients. Drug-induced
autoimmune-like toxicities have been observed in patients
treated with immune checkpoint inhibitors (such as those used
in anti-PD-1 therapy) through the infiltration of immune cells
into normal noncancerous tissues. Immune-related AEs
can affect multiple organs such as the skin, bowel, kid-
ney, peripheral and central nervous system, liver, lymph
nodes, eyes, pancreas, and endocrine tissues. Steroid
therapy is recommended for the management of
immune-related AEs [21, 22]. In the present study, most
AEs were of grade 1 or 2 and were manageable by
interrupting pembrolizumab treatment and/or medical in-
tervention without steroid therapy.
Pembrolizumab exposure at a dose of 10 mg/kg was gen-
erally similar for Japanese and non-Japanese patients with
advanced solid tumors (AUC0-∞: 3410 vs. 3270 μg
day/mL, Cmax: 250 vs. 256 μg/mL, respectively). The
mean CL, t1/2, and Vz values were generally similar
between the two populations for doses in the range 1–
10 mg/kg. In addition, the individual values for AUC0-∞,
Cmax, t1/2, Vz, and CL for doses in the range 1–10 mg/kg
overlapped (Fig. 2) [18]. These results indicated that the PK
of pembrolizumab in Japanese patients with advanced solid
tumors was generally similar to that in non-Japanese patients
with advanced solid tumors.
As an exploratory analysis, the tumor responses were also
evaluated. Partial responses were observed in two of the nine
patients (22.2 %) treated with 10 mg/kg Q2W by an
Baseline: 1 Aug 2013 Cycle 7: 10 Dec 2013
Fig. 3 PET-CT images taken before the start of treatment and after cycle
7 show evidence of antitumor activity. A rapid and durable partial
response according to irRC was observed in a 91-year-old man with
advanced metastatic acral lentiginous melanoma who had active disease
in the liver and multiple lymph nodes when treatment with
pembrolizumab at 10 mg/kg Q2W was initiated
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investigator review according to both RECIST v1.1 and irRC
criteria. One of the five patients with advanced NSCLC and
one of the three patients with advanced melanoma achieved
partial responses. A durable response (response duration of
more than 225 days according to irRC) was observed in one
patient with metastatic acral lentiginous melanoma, which is
the most common subtype of melanoma in Asian countries
(superficial spreading melanoma is more common in
Caucasians). This result is encouraging for the further devel-
opment of pembrolizumab treatment for melanoma in Japan.
Because of the limited number of patients and tumor sam-
ples, a relationship between tumor response and PD-L1 ex-
pression was not observed in the present study. Recent data
have shown that PD-L1 expression, microsatellite instability
high, increased mutation burden, and the immune gene ex-
pression signature are correlated with the improved efficacy
of pembrolizumab [23–26], indicating the importance of bio-
marker development to identify patients suitable for anti-PD-1
and anti-PD-L1 therapy. Based on the safety data from this
phase 1 study, Japanese patients are currently being enrolled in
late-phase global studies of pembrolizumab for the treat-
ment of various types of tumors, such as NSCLC, gas-
tric cancer, head and neck cancer, bladder cancer, and colo-
rectal cancer. Further biomarker analyses in these clinical
studies are on-going.
Recent randomized studies of pembrolizumab demonstrat-
ed that no clinically meaningful differences in the safety and
efficacy of pembrolizumab were evident between 2 mg/kg
Q3W and 10 mg/kg Q3W or between 10 mg/kg Q3W and
10 mg/kg Q2W [27–31] . The adminis t ra t ion of
pembrolizumab at 2 mg/kg Q3W is currently approved in
the United States and other countries for the treatment of pa-
tients with unresectable or metastatic melanoma or metastatic
NSCLC expressing PD-L1.
In conclusion, pembrolizumab at dosages of 2 and 10 mg/
kg Q2W was well tolerated in Japanese patients with ad-
vanced solid tumors and showed encouraging anti-tumor ac-
tivity against melanoma and NSCLC.
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